^
Association details:
| Biomarker: | SF3B1 mutation + Chr del(5q) |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
3122 SF3B1 Mutations and Not TP53 Are Associated with Poor Outcomes in Patients with Del(5q) Myelodysplastic Syndromes (MDS)
Published date:
11/04/2020
Excerpt:
We retrospectively reviewed our database of 132 patients with del(5q) MDS...Multivariate regression confirmed lenalidomide response and SF3B1 status are independently associated with outcomes….SF3B1 mutations, typically correlate with favorable risk in MDS, are associated with significantly worse prognosis compared to WT in patients with del(5q) MDS.
